CG Oncology's Lead Bladder Cancer Drug Offers …

CG Oncology, Inc. (CGON) Stock Price, Quote, News & AnalysisCG Oncology Begins IPO Effort For Bladder Cancer Drug - Seeking Alpha

CouponFollow Extension

$380
OFF

CG Oncology Is First Biotech IPO Of 2024, Raising $380m

4 weeks from now

Jan 25, 2024 · CG Oncology completes the first biotech IPO of 2024, raising $380 million for its oncolytic virus bladder cancer ... to raise around $200 million from an offer of less than 12 …

pharmaphorum.com

$209
OFF

CG Oncology Aims For $209M IPO, As More Biotechs Eye Nasdaq

4 weeks from now

Jan 18, 2024 · Bladder cancer-focused CG kicked off 2024 by outlining plans to go public, although the company didn’t offer any figures at the time. Now, the biotech has said it is …

fiercebiotech.com

$105
OFF

CG Raises $105M Crossover Round To Fund Phase 3 Cancer Trial

4 weeks from now

Aug 2, 2023 · CG Oncology has raised the rarely seen crossover round. Once ubiquitous, the pre-IPO rounds have dried up in the biotech bear market—but CG’s fully enrolled phase 3 bladder …

fiercebiotech.com

$105
OFF

CG Oncology Announces $105 Million Oversubscribed Crossover …

4 weeks from now

Aug 2, 2023 · – Co-led by new investors Foresite Capital and TCGX – – Proceeds to advance late-stage clinical programs in bladder cancer towards FDA approval – August 2, 2023, 8:00 …

cgoncology.com

$380
OFF

Bladder Cancer Biotech CG Oncology Raises $380 Million In IPO

4 weeks from now

Jan 25, 2024 · CG Oncology, a biotech focused on bladder cancer, raised $380 million in its IPO, pricing 20 million shares at $19. Why it matters This is a lustrous green light for the broader …

axios.com

$120
OFF

CG Oncology Raises $120 Million In Oversubscribed Series E …

4 weeks from now

Nov 15, 2022 · In response, CG Oncology has decided to investigate the activity of CG0070 as a first-line treatment of BCG-naïve, Intermediate-Risk NMIBC in a Phase 2 study to expand …

cgoncology.com

FAQs about CG Oncology's Lead Bladder Cancer Drug Offers … Coupon?

Could CG oncology be a new treatment for bladder cancer?

The treatments for bladder cancer haven't changed much since the 1970s. However, Steinberg is advising a startup, CG Oncology based in Irvine, CA, that's developing a potential new treatment: an immunotherapy designed to treat bladder cancer. The company is focused on this treatment. ...

Does persistent overactive bladder indicate cancer?

Frequent urination means that you have to urinate more often than you usually do. 1, 3 This symptom can result from an overactive bladder or a weak bladder. It can happen due to various reasons such as neurological disorders, such as stroke and multiple sclerosis, diabetes, urinary tract infections, hormonal changes during menopause in women, conditions affecting the bladder, such as tumors or bladder stones, factors that get in the way of urine leaving the bladder, such as enlarged prostate, constipation or previous surgery to treat incontinence, medications that cause your body to make a lot of urine or require that you take them with lots of fluids, Drinking too much caffeine or alcohol, Declining cognitive function due to aging, which may make it more difficult for your bladder to understand the signals it receives from your brain, etc. Thus, it need not be a bladder cancer always, but there is a chance of bladder cancer being the reason behind OAB. ...

How big is CG oncology's market for bladder cancer treatment?

The global market for bladder cancer treatment is expected to reach $4.71 billion by 2026. This market growth potential drives opportunities for CG Oncology. I'll provide an update when we learn more IPO details from CG Oncology, Inc. management. Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Learn More » ...

How effective is CG oncology's bladder cancer molecule cretostimogene?

CG Oncology's bladder cancer molecule, cretostimogene, showed high success with a 75.2% complete response rate in a phase 3 monotherapy study. Cretostimogene, an oncolytic immunotherapy, works by sele... ...

Can CG0070 help in curing bladder cancer?

In a phase 2 clinical trial, CG0070 was given to bladder cancer patients who didn’t respond to BCG treatment or had the cancer come back. Forty-seven percent of these high-risk patients saw their cancer completely cleared after 6 months. In a phase 2 clinical trial, CG0070 was tested on bladder cancer patients who didn’t respond to BCG treatment or had the cancer return. ...

Is CG a good treatment for Urologic Oncology?

During the annual meeting of the Society of Urologic Oncology in November, CG reported interim efficacy data showing a complete response rate of 75.7%, or 50 of the 66 evaluable patients. The therapy was generally well tolerated with adverse effects classified as Grade 1 or 2. ...